Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of ...

If you’re in a group being offered the vaccine you will likely get a text reminder from the NHS. Pfizer's Comirnaty and Moderna's Spikevax vaccines are currently the 2 types of vaccines offered in the ...

Finished logos can be instantly downloaded in multiple formats, such as PNG, JPG, SVG, EPS, and PDF, with transparent backgrounds and variations for digital and print use. Beyond logos, Design.com ...

Federal investigators are investigating claims suggesting Pfizer delayed announcing test results of its Covid vaccine until after the 2020 presidential election, the Wall Street Journal reported ...

Pfizer offers a substantial 6.7% dividend yield and has increased its dividend for 16 consecutive years. The stock trades at a forward P/E of just 8.7, close to historical lows. Despite policy ...

Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot’s success in 2020 until after that year’s election, the Wall Street Journal reported ...

A senior GSK scientist, who formerly worked at rival Pfizer, had told GSK colleagues that Pfizer delayed announcing the success of its Covid vaccine in 2020 until after that year’s election.

British drugmaker GSK told Manhattan prosecutors that a former employee told colleagues Pfizer held back positive results until after the 2020 election. But the former employee, who worked at both ...

Pfizer (NYSE:PFE) shares fell on Wednesday after The Wall Street Journal reported that U.S. officials have started an investigation into whether the New York-based pharma giant deliberately ...

Pfizer shares fell 1.32% after reports U.S. prosecutors are investigating claims from GSK about the timing of Pfizer’s COVID-19 vaccine. Pfizer denies allegations of delaying vaccine results for ...

Now given Pfizer's growing pipeline of new drug launches, I think their revenue will likely outgrow the current consensus - the EPS should follow suit in this case as the firm's smart cost ...